Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 3, 2006, Pages 312-317

  Erikson, Anders ^a,d   Forsberg, Håkan ^b   Nilsson, Magnus ^b   Åström, Marianne ^b   Månsson, Jan Eric ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b SUNDERBY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CCL18; Chitotriosidase; Enzyme replacement therapy; Gaucher disease type 3; Glucosylceramide

Indexed keywords

ALGLUCERASE; CHEMOKINE; CHEMOKINE CCL18; CHITOTRIOSIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GAUCHER DISEASE; HUMAN; LONG TERM CARE; MALE; MENTAL DETERIORATION; NEUROLOGIC DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOMETRY; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRAIN DISEASES; CHEMOKINES, CC; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HEXOSAMINIDASES; HUMANS; MALE; TREATMENT OUTCOME;

EID: 33644592963     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250500423804     Document Type: Article

References (21)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AT, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3635-68.
2. Knudson AG Jr, Kaplan WD. Genetics of sphingolipidoses. In: Aronson SM, Volk BW, editors. Cerebral sphingolipidoses. New York: Academic Press; 1962. p. 395-411.
3. Zhao H, Grabowski GA. Gaucher disease: perspectives on a prototype lysosomal disease. Cell Mol Life Sci 2002;59:694-707.
4. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 1982;39:709-18.
5. Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 2002;76:262-70.
6. Schueler UH, Kolter T, Kaneski CR, Bluzsztajn JK, Herkenham M, Sandh K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis 2003;14:595-601.
7. Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease, morphological and biochemical studies. Acta Neuropathol (Berl) 1984;65:99-109.
8. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency - macrophage targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70.
9. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry I, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9.
10. Erikson A, Johansson K, Månsson JE, Svennerholm L. Enzyme replacement therapy of infantile Gaucher disease. Neuropediatrics 1993;24:237-8.
11. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;38:539-47.
12. Erikson A, Bembi B, Schiffman R. Neuronopathic forms of Gaucher's disease. Baillieres Clin Hematol 1997;10:711-23.
13. Campbell PE, Harris CM, Vellodi A. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology 2004;63:385-7.
14. Erikson A. Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 1986;326:1-42.
15. Erikson A, Karlberg J, Skogman AL, Dreborg S. Gaucher disease (type III): intellectual profile. Pediatr Neurol 1987;3:87-91.
16. Boot RG, Verhoek M, de Post M, Hollak CE, Maas M, Bleilevens B, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33-9.
17. Erikson A, Åström M, Månsson JE. Enzyme infusion therapy of the Norrbottnian (Type 3) Gaucher disease. Neuropediatrics 1995;26:203-7.
18. Nilsson O, Håkansson G, Dreborg S, Groth CG, Svennerholm L. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: Significant differences between type I and type III. Clin Genet 1982;22:274-9.
19. Svennerholm L, Fredman P, Jungbjer B, Månsson JE, Rynmark BM, Boström K, et al. Large alterations in ganglioside and neutral glycosphingolipid patterns in brains from cases with infantile neuronal ceroidlipofuscinosis/poly-unsaturated fatty acid lipidosis. J Neurochem 1987;49:1772-83.
20. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity, a novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92.
21. Vellodi A, Bembi B, de Villemeur TB, Collin Histed T, Erikson A, Mengel E, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001;24:319-27.